Skip to main content
Intravenous lanadelumab for the treatment of moderately ill COVID-19 patients.

Engel JJ. British Journal of Clinical Pharmacology 2026;92(6):1685-1695.

Published on 7/6/2026

Tolerability and pharmacokinetics of leritrelvir in Chinese participants with severe renal impairment and healthy matched control subjects.

Zhou ZY. British Journal of Clinical Pharmacology 2026;92(6):1886-1893.

Published on 7/6/2026

MERS-CoV: travel from the Middle East advice sheet.

UK Health Security Agency (UKHSA); 2026.

Published on 19/5/2026

MERS-CoV: biological principles for the control of MERS-CoV.

UK Health Security Agency (UKHSA); 2026.

Published on 19/5/2026

MERS-CoV: clinical management and guidance.

UK Health Security Agency (UKHSA); 2026.

Published on 19/5/2026

MERS-CoV: background information.

UK Health Security Agency (UKHSA); 2026.

Published on 19/5/2026

MERS-CoV: diagnostic testing.

UK Health Security Agency (UKHSA); 2026.

Published on 19/5/2026

MERS-CoV: diagnosis and management of cases and contacts.

UK Health Security Agency (UKHSA); 2026.

Published on 19/5/2026

MERS-CoV: risk assessment.

UK Health Security Agency (UKHSA); 2026.

Published on 19/5/2026


...
5
6
7
8
9
...